​
​

Novartis (NVS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Novartis Revenue Highlights

Latest Revenue (Y)

$46.66B

Latest Revenue (Q)

$11.83B

Main Segment (Y)

Top 20 products

Main Geography (Y)

Americas

Novartis Revenue by Period

Novartis Revenue by Year

DateRevenueChange
2023-12-31--9.97%
2022-12-31--1.98%
2021-12-31-5.97%
2020-12-31-2.51%
2019-12-31--8.44%
2018-12-31-6.05%
2017-12-31-1.41%
2016-12-31--1.89%
2015-12-31--6.05%
2014-12-31--8.83%
2013-12-31-2.21%
2012-12-31--3.06%
2011-12-31-15.15%
2010-12-31-14.32%
2009-12-31-5.92%
2008-12-31-9.34%
2007-12-31-5.98%
2006-12-31-12.98%
2005-12-31-15.15%
2004-12-31-13.61%
2003-12-31-7.40%
2002-12-31-19.74%
2001-12-31--11.44%
2000-12-31-6.93%
1999-12-31--11.38%
1998-12-31--

Novartis generated $46.66B in revenue during NA 2023, up -9.97% compared to the previous quarter, and up 87.76% compared to the same period a year ago.

Novartis Revenue by Quarter

DateRevenueChange
2024-03-31-0.45%
2023-12-31--2.61%
2023-09-30--13.23%
2023-06-30-5.51%
2023-03-31-0.92%
2022-12-31-1.91%
2022-09-30--1.86%
2022-06-30-2.11%
2022-03-31--5.24%
2021-12-31-1.16%
2021-09-30-0.55%
2021-06-30-4.73%
2021-03-31--2.58%
2020-12-31-3.92%
2020-09-30-7.88%
2020-06-30--8.55%
2020-03-31--0.06%
2019-12-31-1.87%
2019-09-30-3.81%
2019-06-30-4.97%
2019-03-31--16.17%
2018-12-31-20.01%
2018-09-30--15.36%
2018-06-30-4.05%
2018-03-31--1.79%
2017-12-31-3.72%
2017-09-30-1.58%
2017-06-30-6.02%
2017-03-31--6.51%
2016-12-31-2.15%
2016-09-30--2.67%
2016-06-30-7.36%
2016-03-31--7.76%
2015-12-31-2.56%
2015-09-30--3.19%
2015-06-30-5.69%
2015-03-31--8.63%
2014-12-31-0.41%
2014-09-30--4.65%
2014-06-30--2.04%
2014-03-31--7.32%
2013-12-31-5.53%
2013-09-30--0.99%
2013-06-30-3.51%
2013-03-31--5.72%
2012-12-31-7.33%
2012-09-30--3.45%
2012-06-30-4.51%
2012-03-31--7.22%
2011-12-31--0.25%
2011-09-30--0.59%
2011-06-30-6.34%
2011-03-31--1.67%
2010-12-31-12.82%
2010-09-30-7.54%
2010-06-30--3.52%
2010-03-31--6.00%
2009-12-31-16.43%
2009-09-30-5.10%
2009-06-30-8.22%
2009-03-31--4.08%
2008-12-31--6.18%
2008-09-30-2.83%
2008-06-30-4.99%
2008-03-31-0.44%
2007-12-31--

Novartis generated $11.83B in revenue during Q1 2024, up 0.45% compared to the previous quarter, and up 90.39% compared to the same period a year ago.

Novartis Revenue Breakdown

Novartis Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 22Dec 21Dec 20Dec 19Dec 18
Total anti-infectives net sales-----
Top 20 products-----
Anti Infectives sold under Sandoz name-----
Rest of portfolio-----
COPD-----

Novartis's latest annual revenue breakdown by segment (product or service), as of Dec 22: Top 20 products (74.27%), Rest of portfolio (21.17%), Total anti-infectives net sales (2.77%), and Anti Infectives sold under Sandoz name (1.80%).

Quarterly Revenue by Product

Product/ServiceJun 23Jun 22Jun 21Jun 20Jun 19
Rest of portfolio-----
Top 20 products-----
Anti Infectives sold under Sandoz name-----
Total anti-infectives net sales-----

Novartis's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Top 20 products (78.18%), and Rest of portfolio (21.82%).

Novartis Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 22Dec 21Dec 20Dec 19Dec 18
Other countries-----
Country of domicile-----
CHINA-----
JAPAN-----
GERMANY-----
FRANCE-----
Americas-----
Europe-----
US-----
UNITED STATES-----
Asia/Africa/Australasia-----
Canada and Latin America-----

Novartis's latest annual revenue breakdown by geography, as of Dec 22: Americas (39.57%), Other countries (36.85%), GERMANY (7.86%), CHINA (5.75%), FRANCE (4.15%), JAPAN (4.05%), and Country of domicile (1.78%).

Quarterly Revenue by Country

CountryJun 19
Asia/Africa/Australasia-

Novartis's latest quarterly revenue breakdown by geography, as of Jun 19: Asia/Africa/Australasia (100.00%).

Novartis Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson--
MRKMerck--
PFEPfizer--
ABBVAbbVie--
NVSNovartis--
AZNAstraZeneca--
BMYBristol-Myers Squibb Company--
SNYSanofi--
LLYEli Lilly and Company--
GSKGSK--
GILDGilead Sciences--

NVS Revenue FAQ

What is Novartis’s yearly revenue?

Novartis's yearly revenue for 2023 was $46.66B, representing a decrease of -9.97% compared to 2022. The company's yearly revenue for 2022 was $51.83B, representing a decrease of -1.98% compared to 2021. NVS's yearly revenue for 2021 was $52.88B, representing an increase of 5.97% compared to 2020.

What is Novartis’s quarterly revenue?

Novartis's quarterly revenue for Q1 2024 was $11.83B, a 0.45% increase from the previous quarter (Q4 2023), and a -10.44% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $11.78B, a -2.61% decrease from the previous quarter (Q3 2023), and a -10.02% decrease year-over-year (Q4 2022). NVS's quarterly revenue for Q3 2023 was $12.09B, a -13.23% decrease from the previous quarter (Q2 2023), and a -5.84% decrease year-over-year (Q3 2022).

What is Novartis’s revenue growth rate?

Novartis's revenue growth rate for the last 3 years (2021-2023) was -11.76%, and for the last 5 years (2019-2023) was -4.14%.

What are Novartis’s revenue streams?

Novartis's revenue streams in c 22 are Total anti-infectives net sales, Top 20 products, Anti Infectives sold under Sandoz name, and Rest of portfolio. Total anti-infectives net sales generated $1.2B in revenue, accounting 2.77% of the company's total revenue, up 9.09% year-over-year. Top 20 products generated $32.14B in revenue, accounting 74.27% of the company's total revenue, down -1.61% year-over-year. Anti Infectives sold under Sandoz name generated $777M in revenue, accounting 1.80% of the company's total revenue, up 9.90% year-over-year. Rest of portfolio generated $9.16B in revenue, accounting 21.17% of the company's total revenue, down -1.84% year-over-year.

What is Novartis’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Novartis was Top 20 products. This segment made a revenue of $32.14B, representing 74.27% of the company's total revenue.